Lipoprotein apheresis – More than just cholesterol reduction?

Geiss, 2005, Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins, Atherosclerosis, 180, 107, 10.1016/j.atherosclerosis.2004.11.007 Gordon, 1994, Indications for low-density lipoprotein apheresis, Am J Cardiol, 74, 1109, 10.1016/0002-9149(94)90461-8 Schettler, 2002, First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management, Ther Apher, 6, 381, 10.1046/j.1526-0968.2002.00426.x Schettler, 2012, Current view: indications for extracorporeal lipoprotein apheresis treatment, Clin Res Cardiol, 7, 15 Tonstad, 2004, Management of hyperlipidemia in the pediatric population, Curr Treat Options Cardiovasc Med, 6, 431, 10.1007/s11936-004-0027-2 Kroon, 1996, Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease, Ann Intern Med, 125, 945, 10.7326/0003-4819-125-12-199612150-00001 Mabuchi, 1998, Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group, Am J Cardiol, 82, 1489, 10.1016/S0002-9149(98)00692-4 Matsuzaki, 2002, Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART), J Am Coll Cardiol, 40, 220, 10.1016/S0735-1097(02)01955-1 Nishimura, 1999, Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS), Atherosclerosis, 144, 409, 10.1016/S0021-9150(98)00328-1 Jovin, 1997, Improvement of myocardial perfusion after low-density lipoprotein apheresis treatment, Eur Heart J, 18, 531, 10.1093/oxfordjournals.eurheartj.a015282 Bosch, 2004, State of the art of low-density lipoprotein apheresis in the year 2003, Ther Apher Dial, 8, 76, 10.1111/j.1526-0968.2003.00120.x Jaeger, 2009, Longitudinal cohort study on the effectiveness of lipoprotein apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events, Nat Clin Pract Cardiovasc Med, 6, 229, 10.1038/ncpcardio1456 Drager, 2005, Internet-based quality assurance registry for LDL apheresis QUASA–the apheresis registry, Transfus Apher Sci, 33, 81, 10.1016/j.transci.2004.03.006 Ridker, 2005, C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, 20, 10.1056/NEJMoa042378 de Beer, 1982, Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction, Br Heart J, 47, 239, 10.1136/hrt.47.3.239 Moriarty, 2001, C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis, Atherosclerosis, 158, 495, 10.1016/S0021-9150(01)00633-5 Wieland, 2002, Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis, Atherosclerosis, 162, 187, 10.1016/S0021-9150(01)00698-0 Kobayashi, 2005, LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects, J Clin Apher, 20, 239, 10.1002/jca.20033 Blaha, 2004, Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity, Physiol Res, 53, 273, 10.33549/physiolres.930460 Rovers, 1998, LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia, Atherosclerosis, 141, 99, 10.1016/S0021-9150(98)00152-X Nguyen, 1985, Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood, Kidney Int, 28, 158, 10.1038/ki.1985.136 Schamberger, 2000, Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia, J Lipid Res, 41, 727, 10.1016/S0022-2275(20)32381-6 Leitinger, 1996, Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment, Atherosclerosis, 126, 305, 10.1016/0021-9150(96)05919-9 Schettler, 1999, Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis, Ther Apher, 3, 219, 10.1111/j.1091-6660.1999.t01-3-.x Mera, 2005, The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst, Biochem Biophys Res Commun, 334, 1322, 10.1016/j.bbrc.2005.07.035 Witko-Sarsat, 2003, Are advanced oxidation protein products potential uremic toxins?, Kidney Int Suppl, S11, 10.1046/j.1523-1755.63.s84.47.x Mellwig, 1998, Improvement of coronary vasodilatation capacity through single LDL apheresis, Atherosclerosis, 139, 173, 10.1016/S0021-9150(98)00055-0 Rosenson, 1998, Effects of lipids and lipoproteins on thrombosis and rheology, Atherosclerosis, 140, 271, 10.1016/S0021-9150(98)00144-0 Schuff-Werner, 2004, Increased red blood cell adhesiveness/aggregation owing to fibrinogen elevation in hypercholesterolaemic patients and the rationale of fibrinogen-lowering by LDL apheresis, Eur J Clin Invest, 34, 378, 10.1111/j.1365-2362.2004.01341.x Kojima, 2001, Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis, Ther Apher, 5, 2, 10.1046/j.1526-0968.2001.005001002.x Pulido, 2005, Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD), J Clin Apher, 20, 185, 10.1002/jca.20047 Suckfull, 2002, Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial, Lancet, 360, 1811, 10.1016/S0140-6736(02)11768-5 Rampino, 1999, Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor, Kidney Int, 56, 2286, 10.1046/j.1523-1755.1999.00791.x Grundtman, 2011, The autoimmune concept of atherosclerosis, Curr Opin Lipidol, 22, 327, 10.1097/MOL.0b013e32834aa0c2 Splettstoesser, 2002, Oxidative stress in phagocytes–“the enemy within”, Microsc Res Tech, 57, 441, 10.1002/jemt.10098 Schettler, 2011, Impact of lipoprotein apheresis on Egr-1, c-Jun, c-Fos, and Hsp70 gene expression in white blood cells, Ther Apher Dial, 15, 105, 10.1111/j.1744-9987.2010.00861.x